Research Topics
Genomes and GenesSpecies | Dean WingerchukSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Neuromyelitis optica: potential roles for intravenous immunoglobulinDean M Wingerchuk
Department of Neurology, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
J Clin Immunol 33:S33-7. 2013..The rationale and potential role for intravenous immunoglobulin in NMO will be discussed in the context of both relapse treatment and relapse prevention...
Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosisDean M Wingerchuk
Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Curr Opin Neurol 20:343-50. 2007..We review recent progress in differentiating and understanding the disease mechanisms of acute disseminated encephalomyelitis, neuromyelitis optica, and classical multiple sclerosis...
Neuromyelitis optica: effect of genderDean M Wingerchuk
Mayo Clinic College of Medicine, Scottsdale, AZ 85259, United States
J Neurol Sci 286:18-23. 2009..Population-based epidemiological and genetic studies, with case ascertainment aided by the high specificity of NMO-IgG and consistent disease definitions, are needed to better define and understand gender effects in neuromyelitis optica...
Hemi-meningitis: A focal sign heralding a multisystem necrotizing vasculitisDean M Wingerchuk
Department of Neurology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
Neurology 70:2014. 2008
The spectrum of neuromyelitis opticaDean M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Lancet Neurol 6:805-15. 2007..The knowledge gained from further assessment of the exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic trials for this rapidly disabling disease...
Multiple sclerosis disease-modifying therapies: adverse effect surveillance and managementDean M Wingerchuk
Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Expert Rev Neurother 6:333-46. 2006..These skills will become increasingly important to those caring for MS patients as contemporary treatment regimens become increasingly complex...
Neuromyelitis opticaDean M Wingerchuk
Dean M Wingerchuk, MD, MSc, FRCP C Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Curr Treat Options Neurol 10:55-66. 2008..We also recommend immunosuppression for at least 5 years in NMO-IgG seropositive patients presenting with a first-ever attack of longitudinally extensive transverse myelitis because they are at high risk for relapse or conversion to NMO...
Current evidence and therapeutic strategies for multiple sclerosisDean M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Semin Neurol 28:56-68. 2008....
The clinical course of acute disseminated encephalomyelitisDean M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Neurol Res 28:341-7. 2006....
Evidence for humoral autoimmunity in neuromyelitis opticaDean M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Neurol Res 28:348-53. 2006..This evidence is reviewed in the context of its implications for future laboratory and clinical research in NMO...
Revised diagnostic criteria for neuromyelitis opticaD M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Neurology 66:1485-9. 2006..A serum autoantibody marker, NMO-IgG, is highly specific for NMO. The authors propose revised NMO diagnostic criteria that incorporate NMO-IgG status...
Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirinDean M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Arch Neurol 63:1005-8. 2006..Many women with multiple sclerosis (MS) experience transient neurologic symptom worsening and fatigue in conjunction with the menstrual cycle. Aspirin reduces MS fatigue in some patients...
Diagnosis and treatment of neuromyelitis opticaDean M Wingerchuk
Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Neurologist 13:2-11. 2007..Several clinical, laboratory, and neuroimaging characteristics may accurately distinguish NMO from MS early in the disease course...
Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topicDean M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Neurologist 13:231-3. 2007..To determine whether migraine with aura and migraine without aura are independent risk factors for symptomatic cardiovascular and cerebrovascular disease...
A secondary progressive clinical course is uncommon in neuromyelitis opticaD M Wingerchuk
Department of Neurology, Mayo Clinic College of Medicine, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Neurology 68:603-5. 2007..00002; relative risk = 0.08). The disparate natural histories of MS and NMO suggest dissociation between relapses and clinical progression in CNS demyelinating diseases...
Neuromyelitis opticaD M Wingerchuk
Multiple Sclerosis Center Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
Int MS J 13:42-50. 2006..Relapsing NMO has a poor prognosis; therapy, typically with immunosuppression, is necessary as early as possible in the disease course to prevent attack-related disability...
Progressive cervical myelopathy secondary to chronic ventriculoperitoneal CSF overshuntingD M Wingerchuk
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85255, USA
Neurology 65:171-2. 2005
Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measuresD M Wingerchuk
Mayo Medical School, Rochester, Minnesota, USA
Neuroimaging Clin N Am 10:611-24 ,vii. 2000..This article reviews the current state of knowledge of MS epidemiology, genetics, disease classification, natural history, and outcome measures...
Cannabis for medical purposes: cultivating science, weeding out the fictionDean Wingerchuk
Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Lancet 364:315-6. 2004
Neuromyelitis optica: clinical predictors of a relapsing course and survivalDean M Wingerchuk
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Neurology 60:848-53. 2003..Early prediction of a relapsing course and subsequent disease severity would facilitate design and implementation of clinical trials of such therapies...
A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosisD M Wingerchuk
Mayo Clinic, Scottsdale, Arizona, USA
J Neurol Neurosurg Psychiatry 76:1294-6. 2005..Epidemiological and ecological studies suggest links between vitamin D deficiency and increased multiple sclerosis (MS) prevalence...
Postinfectious encephalomyelitisDean M Wingerchuk
Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Curr Neurol Neurosci Rep 3:256-64. 2003..The differences between childhood and adult ADEM, risks of development of multiple sclerosis, and the contributions of recent studies to refining the nosology of CNS demyelinating syndromes are discussed...
Neuromyelitis optica: current conceptsDean M Wingerchuk
Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
Front Biosci 9:834-40. 2004..Advances in understanding of its natural history and pathophysiology may eventually allow determination of whether idiopathic NMO represents a specific disease. This article summarizes recent progress in these areas of NMO research...
Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smokingDean M Wingerchuk
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Mt Sinai J Med 78:221-30. 2011..This review summarizes current evidence for these 3 putative multiple sclerosis risk factors and early attempts to develop risk models and examine gene-environment interactions for this complex disease...
A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosisD M Wingerchuk
Department of Neurology Mayo Clinic, Scottsdale, AZ 85259, USA
Neurology 64:1267-9. 2005..012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue...
Low serum vitamin D levels and recurrent inflammatory spinal cord diseaseMaureen A Mealy
Department of Neurology, Johns Hopkins University, 600 N Wolfe Street, Baltimore, MD 21287, USA
Arch Neurol 69:352-6. 2012..As a sterol hormone involved in multiple immunologic pathways, vitamin D may play a role in preventing monophasic immune-mediated central nervous system attacks from developing into recurrent disease...
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritisJ H Noseworthy
Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Neurology 56:1514-22. 2001..To determine whether IV immunoglobulin (IVIg) reverses chronic visual impairment in MS patients with optic neuritis (ON)...
NMO-IgG predicts the outcome of recurrent optic neuritisM Matiello
Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Neurology 70:2197-200. 2008..Recurrent ON may herald multiple sclerosis (MS) or NMO, or it may occur as an isolated syndrome. The prognosis and response to therapy differs in each of these contexts...
Is there a neurologist on this flight?J I Sirven
Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
Neurology 58:1739-44. 2002..To analyze the frequency of neurologic events during commercial airline flights and to assess whether onboard emergency medical kits are adequate for in-flight neurologic emergencies...
Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody markerB G Weinshenker
Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55901, USA
Curr Top Microbiol Immunol 318:343-56. 2008....
Neuromyelitis opticaMark J Morrow
Department of Neurology, Harbor UCLA Medical Center, Torrance, CA, USA
J Neuroophthalmol 32:154-66. 2012..Hopefully, the future will bring more sensitive tools for defining risk and predicting outcome, as well as more targeted and effective forms of therapy...
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker
Department of Neurology, The Ohio State University Medical Center, Columbus, USA
Ann Neurol 66:460-71. 2009..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis opticaClaudia F Lucchinetti
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Brain 125:1450-61. 2002..Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation...
Is obstructive sleep apnea an independent risk factor for stroke? A critically appraised topicDan J Capampangan
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Neurologist 16:269-73. 2010..Obstructive sleep apnea (OSA) is associated with hypertension, atrial fibrillation, coronary artery disease, congestive heart failure, and diabetes. These disorders are also risk factors for stroke...
Epidemiology and natural history of multiple sclerosis: new insightsOrhun Kantarci
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
Curr Opin Neurol 19:248-54. 2006..Further refinements will eventually allow powerful longitudinal studies to assess genetic and environmental interactions with implications for prediction of individual disease susceptibility, clinical course, and response to therapy...
Multiple sclerosis: current pathophysiological conceptsD M Wingerchuk
Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
Lab Invest 81:263-81. 2001....
Migraine with and without aura and risk for cardiovascular diseaseBert B Vargas
Department of Neurology, Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
Curr Atheroscler Rep 10:427-33. 2008....
Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders?Jonathan H McKinnon
Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
Neurologist 13:382-5. 2007..A recent American Academy of Neurology practice parameter indicated that olfactory testing was "probably useful" for differentiating idiopathic Parkinson disease (IPD) from other diseases with features of parkinsonism...
Neuromyelitis optica and non organ-specific autoimmunitySean J Pittock
Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
Arch Neurol 65:78-83. 2008..Neuromyelitis optica (NMO) is often associated with other clinical or serological markers of non-organ-specific autoimmunity...
Establishing a diagnosis of benign paroxysmal positional vertigo through the dix-hallpike and side-lying maneuvers: a critically appraised topicRashmi B Halker
Department of Neurology, Division of Education Administration, Mayo Clinic, Scottsdale, Arizona 85259, USA
Neurologist 14:201-4. 2008..Benign paroxysmal positional vertigo (BBPV) is one of the most common types of vertigo. Although the clinical presentation of this common condition is straightforward, the diagnosis and diagnostic maneuvers can be challenging...
Neuromyelitis optica: new findings on pathogenesisDean M Wingerchuk
Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Int Rev Neurobiol 79:665-88. 2007..Other immunologic differences among NMO, NMO-spectrum disorders, and classical MS are reviewed...
Alpha-lipoic acid may improve symptomatic diabetic polyneuropathyJunger Tang
Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA
Neurologist 13:164-7. 2007..In patients with symptomatic diabetic polyneuropathy, is oral alpha-lipoic acid (ALA) effective in improving neuropathic symptoms compared with placebo?..
Does cervical manipulative therapy cause vertebral artery dissection and stroke?Madeline L Miley
Division of Neurosciences, Faculty of Science, Loyola University, Chicago, IL, USA
Neurologist 14:66-73. 2008..Does cervical manipulative therapy (CMT) cause vertebral arterial dissection (VAD) and subsequent ischemic stroke? What is the best estimate of the incidence of CMT associated with VAD and ischemic stroke?..
Neuromyelitis opticaMarcelo Matiello
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Curr Opin Neurol 20:255-60. 2007..We concentrate on a recently identified serum antibody biomarker, neuromyelitis optica immunoglobulin G (NMO-IgG), which distinguishes neuromyelitis optica from multiple sclerosis...
OSMS is NMO, but not MS: proven clinically and pathologicallyBrian G Weinshenker
Lancet Neurol 5:110-1. 2006
Neuromyelitis opticaDean M Wingerchuk
Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
Adv Neurol 98:319-33. 2006
Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issuesDean M Wingerchuk
Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
Adv Neurol 98:303-18. 2006
Acute transverse myelitis: is the "idiopathic" form vanishing?Bruce A C Cree
Neurology 65:1857-8. 2005
Spinal cord astrocytoma presenting as "idiopathic" intracranial hypertensionAlyx Porter
Department of Neurology, Mayo Clinic, Rochester, 200 1st Street SW, Rochester, MN 55905, USA
Clin Neurol Neurosurg 108:787-9. 2006..This case illustrates that increased intracranial pressure may in exceptional cases of spinal tumors precede the more typical myelopathic presentation by months and mimic idiopathic intracranial hypertension...
Practical consultations: multiple sclerosisDean M Wingerchuk
Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
Semin Neurol 23:253-64. 2003..A general approach, supported by evidence where possible, to common and contemporary clinical issues in MS care is provided in a case-based narrative...
Remission, intractability, and antiepileptic-drug withdrawalDean M Wingerchuk
Lancet Neurol 4:390-1. 2005
Seizure prophylaxis in patients with brain tumors: a meta-analysisJoseph I Sirven
Department of Neurology Mayo Clinic College of Medicine, Scottsdale, Ariz, USA
Mayo Clin Proc 79:1489-94. 2004..To assess whether antiepileptic drugs (AEDs) should be prescribed to patients with brain tumors who have no history of seizures...
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisVanda A Lennon
Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
Lancet 364:2106-12. 2004..We assessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple sclerosis...
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitisBrian G Weinshenker
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Ann Neurol 59:566-9. 2006..We investigated whether neuromyelitis optica (NMO) IgG seropositivity at the initial presentation of longitudinally extensive transverse myelitis (LETM) predicts relapse of myelitis or development of optic neuritis...
Brain abnormalities in neuromyelitis opticaSean J Pittock
Department of Neurology, Laboratory Medicine and Pathology, Radiology, and Immunology, Mayo Clinic College of Medicine, Rochester, Minn, USA
Arch Neurol 63:390-6. 2006..CONCLUSIONS: Asymptomatic brain lesions are common in NMO, and symptomatic brain lesions do not exclude the diagnosis of NMO. These observations justify revision of diagnostic criteria for NMO to allow for brain involvement...
Not every patient with multiple sclerosis should be treated at time of diagnosisSean J Pittock
Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Arch Neurol 63:611-4. 2006
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expressionSean J Pittock
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905 0001, USA
Arch Neurol 63:964-8. 2006..Although it is conventionally believed that the brain is spared, brain imaging abnormalities are not uncommon in patients with NMO...
NMO-IgG: a specific biomarker for neuromyelitis opticaBrian G Weinshenker
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Dis Markers 22:197-206. 2006....
Treatment of vascular dementia and vascular cognitive impairmentBart M Demaerschalk
Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
Neurologist 13:37-41. 2007..and vascular cognitive impairment, are acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and N-methyl-d-aspartate (NMDA) receptor antagonists (memantine) effective in improving cognitive function over placebo?..
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosisShanu F Roemer
Department of Neurology, Mayo Clinic, College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Brain 130:1194-205. 2007..These findings strongly support a role for a complement activating AQP4-specific autoantibody as the initiator of the NMO lesion, and further distinguish NMO from MS...
Second-generation antiepileptic drugs' impact on balance: a meta-analysisJoseph I Sirven
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Ariz, USA
Mayo Clin Proc 82:40-7. 2007..To systematically review available evidence regarding whether second-generation antiepileptic drugs (AEDs) contribute to the risk of balance disorders...
Randomized controlled trials to assess therapies for multiple sclerosisDean M Wingerchuk
Department of Neurology, Mayo Clinic and Mayo Foundation, Scottsdale, AZ 55905, USA
Neurology 58:S40-8. 2002....
Neuromyelitis optica: changing conceptsAnu Jacob
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Neuroimmunol 187:126-38. 2007..The development of animal models and further analysis of the association of NMO-IgG with disease severity and treatment response will elucidate the pathobiology of NMO...
"Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseasesMark G Hickey
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
Neurologist 13:98-101. 2007..To determine whether a diagnosis of idiopathic rapid-eye-movement sleep behavior disorder (RBD) is associated with a future risk of development of neurodegenerative diseases...
The MERITs of evidence-based clinical practice in neurologyBart M Demaerschalk
Mayo Clinic College of Medicine, Scottsdale, Arizona 85255, USA
Semin Neurol 27:303-11. 2007....
Critically appraised topics: the evidence-based neurologistDean M Wingerchuk
Neurologist 13:1. 2007
Clinical predictors of psychogenic nonepileptic seizures: a critically appraised topicMatthew T Hoerth
Department of Neurology, Division of Education Administration, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
Neurologist 14:266-70. 2008..Identification of clinical features that reliably distinguish PNES from ES would be valuable in acute care settings, for patients that have coexisting disorders, and those with multiple event types...
